Hudson Edge Investment Partners’s Myriad Genetics MYGN Stock Holding History

Hudson Edge Investment Partners’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-107,030	Closed	-$3.79M	–	152
2015 Q1	$3.79M	Sell	107,030 -67,856	-39%	-$2.43M	0.16%	87
2014 Q4	$5.96M	Sell	174,886 -37,107	-18%	-$1.32M	0.22%	89
2014 Q3	$8.18M	Sell	211,993 -1,600	-0.7%	-$59.7K	0.3%	72
2014 Q2	$8.31M	Buy	213,593 +2,563	+1%	+$95.4K	0.3%	68
2014 Q1	$7.21M	Sell	211,030 -1,950	-0.9%	-$60.4K	0.27%	75
2013 Q4	$4.47M	Sell	212,980 -10,020	-4%	-$253K	0.17%	90
2013 Q3	$5.24M	Sell	223,000 -5,655	-2%	-$161K	0.22%	86
2013 Q2	$6.14M	Buy	+228,655	New	+$6.63M	0.24%	80

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hudson Edge Investment Partners's MYGN Position: Q2 2015 in Review

Hudson Edge Investment Partners sold out of Myriad Genetics (MYGN) in Q2 2015, closing a stake of 107,030 shares — an estimated $3.79M sold.

Hudson Edge Investment Partners first reported a position in MYGN in Q2 2013 and held it in 8 quarters. The position peaked at $8.31M in Q2 2014. 234 funds tracked by Wall St. Rank hold MYGN as of Q2 2015.

Hudson Edge Investment Partners reported no remaining Myriad Genetics position as of Q2 2015 after selling out during the quarter.
Hudson Edge Investment Partners sold 107,030 Myriad Genetics shares in Q2 2015, an estimated $3.79M.
Hudson Edge Investment Partners first reported a position in Myriad Genetics in Q2 2013 and held it in 8 quarters.
Hudson Edge Investment Partners's Myriad Genetics position peaked at $8.31M in Q2 2014.
234 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2015.

Based on Hudson Edge Investment Partners's 13F filing for Q2 2015, filed 5 Aug 2015.